Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2024-11-01 Epub Date: 2024-06-14 DOI:10.1007/s12020-024-03905-1

Ignacio Fuentes, Roberto Santana, Martin Espinoza, Eugenio Arteaga, Thomas Uslar, Rene Baudrand, Gilberto González, Francisco J Guarda, Nicole Lustig, Lorena Mosso, Flavia Nilo, Felipe Valenzuela, Francisco Domínguez, Hernán Eugenio González, Pablo H Montero, Francisco Cruz, Antonieta Solar, José M Domínguez

{"title":"Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.","authors":"Ignacio Fuentes, Roberto Santana, Martin Espinoza, Eugenio Arteaga, Thomas Uslar, Rene Baudrand, Gilberto González, Francisco J Guarda, Nicole Lustig, Lorena Mosso, Flavia Nilo, Felipe Valenzuela, Francisco Domínguez, Hernán Eugenio González, Pablo H Montero, Francisco Cruz, Antonieta Solar, José M Domínguez","doi":"10.1007/s12020-024-03905-1","DOIUrl":null,"url":null,"abstract":"Purpose: Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile.Methods: We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment.Results: Eighty-two patients followed for a median of 2.3 years (0.5-7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response.Conclusion: In a developing country, TL is an adequate option for appropriately selected DTC patients.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"692-698"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-03905-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile.

Methods: We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment.

Results: Eighty-two patients followed for a median of 2.3 years (0.5-7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response.

Conclusion: In a developing country, TL is an adequate option for appropriately selected DTC patients.

Abstract Image

查看原文本刊更多论文

分化型甲状腺癌患者的甲状腺叶切除术：智利一家三级中心的经验。

目的：甲状腺腺叶切除术（TL）是治疗长达 4 厘米的甲状腺内分化型甲状腺癌（DTC）的适当方法。在第一世界中心以外的地区，有关甲状腺叶切除术的数据很少。我们的目的是报告在智利接受TL治疗的DTC患者队列：我们纳入了接受TL治疗的DTC患者，对他们进行了至少6个月的随访，总结了他们的临床病理特征，并对他们的复发风险和治疗反应进行了分类：82名患者的随访时间中位数为2.3年（0.5-7.0年）。73例（89%）患者为乳头状DTC，8例（9.8%）为滤泡状DTC，1例（1.2%）为高级别DTC。56名（68.3%）患者的复发风险较低，26名（31.7%）患者的复发风险处于中等水平。8名（9.8%）患者需要尽早完成甲状腺切除术和放射性碘治疗。在最后一次随访中，52 例（70.3%）反应良好，19 例（25.7%）反应不确定，1 例（1.4%）反应不完全：结论：在发展中国家，对于经过适当选择的 DTC 患者来说，TL 是一种适当的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.